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Cannabinoid receptor CB2 ablation protects 
against TAU induced neurodegeneration
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Abstract 
Tauopathies are a group of neurodegenerative diseases characterized by the alteration/aggregation of TAU protein, 
for which there is still no effective treatment. Therefore, new pharmacological targets are being sought, such as ele‑
ments of the endocannabinoid system (ECS). We analysed the occurrence of changes in the ECS in tauopathies and 
their implication in the pathogenesis. By integrating gene expression analysis, immunofluorescence, genetic and 
adeno‑associated virus expressing TAU mouse models, we found a TAU‑dependent increase in  CB2 receptor expres‑
sion in hippocampal neurons, that occurs as an early event in the pathology and was maintained until late stages. 
These changes were accompanied by alterations in the endocannabinoid metabolism. Remarkably,  CB2 ablation in 
mice protects from neurodegeneration induced by hTAU P301L overexpression, corroborated at the level of cognitive 
behaviour, synaptic plasticity, and aggregates of insoluble TAU. At the level of neuroinflammation, the absence of 
 CB2 did not produce significant changes in concordance with a possible neuronal location rather than its classic glial 
expression in these models. These findings were corroborated in post‑mortem samples of patients with Alzheimer’s 
disease, the most common tauopathy. Our results show that neurons with accumulated TAU induce the expression of 
the  CB2 receptor, which enhances neurodegeneration. These results are important for our understanding of disease 
mechanisms, providing a novel therapeutic strategy to be investigated in tauopathies.
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Background
TAU protein is the major component of the intracellular 
filamentous deposits that characterize several neurode-
generative diseases termed tauopathies, which include 
Alzheimer’s disease (AD), frontotemporal lobar degen-
eration (FTLD-TAU), progressive supranuclear palsy, 
corticobasal degeneration, among others [42]. In general, 
alterations in synaptic plasticity, cell death, proteinopa-
thy, and neuroinflammation are common features in 
tauopathies. Pathogenic mutations in the TAU-encoding 
MAPT gene underlying familial frontotemporal dementia 
(FTD), such as TAU P301L or TAU P301S, have supported the 
generation of multiple mouse models that recapitulate 
pathological and/or behavioural aspects of this disease. 
These TAU mutations reduce the ability of the protein 
to interact with microtubules and increase its propensity 
to assemble into abnormal filaments. On the other hand, 
there are other tauopathies where the dysregulation of 
TAU protein derives from different posttranslational 
changes, e.g. hyperphosphorylation, inducing the forma-
tion of neurofibrillary tangles, harmful to the neuron, as 
in the case of AD. Despite the huge efforts made to find 
a therapy, there is still no effective treatment for tauopa-
thies, so finding neuroprotective treatments for these 
incapacitating diseases have become a priority. Actually, 
the failure of different clinical trials with drugs targeting 
Open Access
*Correspondence:  ilbecker@iib.uam.es
1 Department of Biochemistry, School of Medicine, Universidad 
Autónoma de Madrid (UAM), Spain. Instituto de Investigación Sanitaria La 
Paz (IdiPaz), Instituto de Investigaciones Biomédicas “Alberto Sols” UAM‑
CSIC, C/ Arturo Duperier, 4, 28029 Madrid, Spain
Full list of author information is available at the end of the article
Page 2 of 18Galán‑Ganga et al. acta neuropathol commun            (2021) 9:90 
TAU protein has pointed out the need for finding innova-
tive therapeutic approaches [18].
Over the last decades, the endocannabinoid system 
(ECS), in particular some of its receptors and hydrolys-
ing enzymes, has emerged as a new promising target for 
neurodegenerative diseases [10, 29, 57]. Recent studies 
have shown that the ECS modulates synaptic plasticity, 
as well as the neuronal homeostasis, integrity, and sur-
vival, which may be of great interest in disorders involv-
ing neurodegeneration and neuroinflammation [1]. 
The ECS is formed by two G protein-coupled receptors 
named cannabinoid receptor type-1  (CB1) and type-2 
 (CB2), their ligands and the enzymes responsible for their 
synthesis and degradation. Endocannabinoids (ECs) are 
amides, esters, and ethers of long-chain polyunsaturated 
fatty acids that act as lipid mediators [9], with N-arachi-
donoyl ethanolamine (AEA, or anandamide) and 2-ara-
chidonoylglycerol (2-AG) being the main endogenous 
ligands of cannabinoid receptors. AEA is synthesized 
from N-arachidonoyl phosphatidylethanolamine (NAPE) 
due to the action of a specific NAPE-phospholipase D 
(NAPE-PLD), whereas diacylglycerol lipases α and β 
(DAGL α/β) are responsible for the synthesis of 2-AG 
from diacylglycerol (DAG) substrates (Fig. 3a). Intracellu-
lar degradation of both ECs is triggered by many different 
enzymes, with fatty acid amide hydrolase (FAAH), which 
acts on 2-AG and, in particular, on AEA, and monoacyl-
glycerol lipase (MAGL), which act specifically on 2-AG, 
as the most active [9] (Fig.  3a). Also, ECs may serve as 
precursors for the synthesis of novel signaling lipids (e.g. 
prostamides, prostaglandin-glyceryl esters) when they 
behave as substrates for arachidonate-related enzymes 
as cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-
LOX) (Fig. 3a).
Cannabinoid receptors have been identified as possible 
therapeutic targets against different neurodegenerative 
disorders with very positive results in preclinical stud-
ies [37, 38, 40, 46, 60]. This has included the activation 
of both  CB1 and  CB2 receptors, although the overacti-
vation of  CB1 receptors can lead to detrimental psycho-
tropic effects. Moreover, it has been described a dual 
neuroprotective/neurotoxic profile of cannabinoid drugs, 
for example with Δ9‐tetrahydrocannabinol [15, 61]. By 
contrast, activation of  CB2 receptors does not appear to 
produce these serious adverse effects, although most of 
compounds with  CB2 affinity also share affinity for  CB1 
subtype [63]. Therefore, selective modulation of  CB2 
receptors has aroused great interest to exert those ben-
eficial effects without alterations in mood or perception 
[13].
CB2 cannabinoid receptors have been traditionally 
found in higher levels in cells from the immune sys-
tem and microglia [30], where they participate in the 
modulation of inflammation [16, 48]. However, recent 
publications have pointed their expression in neurons 
of the central nervous system, despite the problems of 
specificity shown by the different antibodies developed 
so far (review [8]). Using additional methodological 
tools (e.g. fluorescence in  situ hybridization; proximity 
ligand assays), a neuronal location for the  CB2 receptor 
has been much more proved in some specific neuronal 
subpopulations [64]. This recent presence in neurons has 
facilitated the involvement of  CB2 receptors in the modu-
lation of different neurobiological processes, for exam-
ple, neuroplasticity and memory [44], processes that are 
also impaired in tauopathies. Interestingly, it has been 
found that  CB2 receptors are selectively overexpressed 
in cells associated with amyloid-β (Aβ) enriched neuritic 
plaques in AD samples from postmortem human brains 
[11]. Nevertheless, the specific effects that TAU protein 
dysregulation may have on  CB2 expression and activities 
have not been well established yet.
In this work, we focused on the relation between dys-
regulated TAU and  CB2 receptors in different tauopathy 
mouse models. We also wanted to explore this relation 
in post-mortem human brain samples of tauopathies, 
in particular from TAU-dependent FTD, but sam-
ples from this specific pathology are difficult to obtain 
due to its low incidence, so we have to concentrate this 
study in AD, whose samples are easier to be collected. 
First, we analysed whether TAU overexpression modu-
lates  CB2 receptor expression in early and late-stage 
tauopathy mouse models and determined whether this 
effect is TAU-dependent. Secondly, we studied whether 
hTAU P301L overexpression could alter ECS signalling. 
Due to the possible role that  CB2 may have in memory 
[65] and the potential of this receptor and other ele-
ments of the ECS to exert neuroprotection by blocking 
of microglial activation [56], we elucidated whether the 
induction of  CB2 receptors and their activation could 
have a positive or negative effect on the progression of 
tauopathy-associated neurodegeneration. For this pur-
pose, we analysed the involvement of the  CB2 receptor 
in the neurodegeneration induced by hTAU P301L using 
 CB2-deficient mice. We compared the cognitive impair-
ment induced by hTAU P301L between wild type (Cnr2+/+) 
and  CB2-knockout (Cnr2−/−) mice and the results were 
correlated with the phosphorylation and aggregation 
status of TAU. Furthermore, we studied the implication 
of  CB2 in the neuroinflammatory process in this model, 
given the classic role assigned to this receptor concerning 
the control of glial activation and reactivity [48]. Finally, 
we wanted to translate the issue to the human pathol-
ogy scenario by determining whether  CB2 levels could be 
altered in postmortem samples from the hippocampus of 
AD patients, the most common tauopathy.
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Overall, our work offers timely insight into the role of 
 CB2 receptor in tauopathies and highlights pharmacolog-




7 and 12-month-old transgenic mice overexpress-
ing hTAU P301S protein (B6;C3-Tg(Prnp-MAPT*P301S)
PS19Vle/J, The Jackson Laboratory) and 10-month-old 
TAU-knockout mice (B6.129X1-Mapttm1Hnd/J, The 
Jackson Laboratory) were used. Tg- hTAU P301S carried a 
mutant (P301S) human microtubule-associated protein 
tau (MAPT) gene driven by the mouse prion-protein 
promoter (Prnp). These animals showed progressively 
accumulated TAU in association with striking neu-
ron loss as well as hippocampal and entorhinal cortical 
atrophy by 9–12 months of age [69]. Each experimental 
group comprised 4–5 mice. Regarding the experiments 
with  CB2-knockout mice [45], each experimental group 
comprised 22–30 wild type mice (C57BL/6 J, The Jackson 
Laboratory) and 19–21  CB2-knockout mice of 6 months 
of age. Recombinant adeno-associated viral vectors of 
serotype 6, which express hTAU P301L under control of 
the human synapsin 1 gene promoter (AAV-hTAU P301L), 
were injected in the right hippocampus (ipsilateral side) 
as described elsewhere [21]. In brief, 2 μL of viral suspen-
sion containing 2.1 × 10E11 GC/ml were injected at the 
stereotaxic coordinates − 1.94 mm posterior, − 1.4 mm 
lateral, and − 1.8 mm ventral relative to bregma. Three 
weeks after injection, mice were sacrificed, and the left 
side (contralateral side) was used as a control. All experi-
ments were performed in a P2 biosafety facility and by 
certified researchers according to regional, national, 
and European regulations concerning animal welfare 
and animal experimentation, and were authorized by 
the Ethics Committee for Research of the Universidad 
Autónoma de Madrid and the Comunidad Autónoma de 
Madrid, Spain, with Ref PROEX 279/14, following insti-
tutional, Spanish and European guidelines (Boletín Ofi-
cial del Estado (BOE) of 18 March 1988 and 86/609/EEC, 
2003/65/EC European Council Directives).
Randomization and blinding
Animals were randomized for treatment. Data collection 
and evaluation of all experiments were performed blindly 
of the group identity. The data and statistical analysis 
with the recommendations on experimental design and 
analysis in pharmacology [23].
Analysis of mRNA levels by quantitative real‑time PCR
Total RNA extraction, reverse transcription, and quan-
titative polymerase chain reaction (qRT-PCR) was done 
as detailed in previous articles [21, 39]. Briefly, total RNA 
was extracted using TRIzol® reagent according to the 
manufacturer’s instructions (Invitrogen). One microgram 
of RNA from each experimental condition was treated 
with DNase (Invitrogen) and reverse-transcribed using 
11 µl high capacity RNA-to-cDNA Master Mix (Applied 
Biosystem). Primer sequences are shown in Additional 
file  4: Table  S1. Data analysis was based on the ΔΔCT 
method with normalization of the raw data to house-
keeping genes (Applied Biosystems). All PCRs were per-
formed in triplicates.
Quantification of EC levels by LC–MS
In brief, frozen ipsilateral and contralateral hippocampi 
from wild type mice injected unilaterally with AAV-
hTAU P301L were weighed and homogenized in metha-
nol containing 5 μl of N-arachidonoyl ethanolamine-d8 
(AEA-d8), 2-arachidonoylglycerol-d8 (2-AG-d8) and 
1-arachidonoylglycerol-d8 (1-AG-d8) (Cayman Chemi-
cal) as internals standards. Lipids were extracted with 
chloroform:  H2O 0.1% Formic Acid 2:1. The organic 
phase was collected and dried in SpeedVac at 60 °C 
and samples were reconstituted in methanol for Liquid 
Chromatography-Mass Spectrometry (LC–MS) analy-
ses. Samples were analysed by LC–MS using an Acquity 
H class (UPLC H-Class, Waters) online QTrap 4500 sys-
tem (Sciex), and Acquity HSS T3 column (1.2 × 100 mm 
and 1.8 µm), as described elsewhere [53]. Briefly, a total 
of 5 μl of the stock solution containing extracted EC was 
injected and separated using precolumn and column 
with mobile phase A (0.1% formic acid in double distilled 
water Milli-Q, Millipore System) and mobile phase B 
(acetonitrile, Merck). The mass spectrometer was oper-
ated in positive ionization mode. For the quantification 
of EC, two calibration curves were realized using com-
mercial EC standards. Individual signals were normalized 
based on total weight to account for sample variability 
and normalized peak areas for internal standard (Multi-
Quant software, Sciex).
Behavioural test
The novel object recognition (NOR) test was used 
to assess recognition memory and was performed as 
described [43]. Briefly, the first day mice were placed in 
the empty open field and were allowed to explore the 
open field for 5 min. as short habituation. 24 h after, mice 
were placed in the open field with two identical objects 
for 7 min, as familiarization session. Finally, the third 
day mice were placed in the open field test where one 
of the objects has been replaced by a novel object for 7 
min, as test session. The amount of time spent explor-
ing the novel (TN) or familiar (TF) object was recorded 
and the differences were represented as Discrimination 
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Index (DI). DI allows discrimination between the novel 
and familiar objects: [DI = (TN − TF)/(TN + TF)]. Each 
experimental group comprised 8–15 animals and the test 
was performed once two days before sacrifice.
Immunofluorescence on mouse tissues
Mouse tissue was sectioned at 30 µm on a cryostat and 
stained as free floating sections using Netwell baskets 
[3]. Briefly, sections were washed on TBS (Tris Buffered 
Saline) and followed by permeabilization in TBS supple-
mented with 0.05% Triton X-100 (TBS-T). After wash-
ing, citric acid-based antigen retrieval for 20 min at 94°C 
was performed. Following antigen retrieval, sections 
were cooled to room temperature (RT), washed 3 times 
in TBS-T, and incubated in blocking buffer (TBS-T sup-
plemented with 5% normal donkey serum and 1% bovine 
serum albumin [BSA]) at RT for 2 h. Sections were then 
incubated in primary antibody solutions diluted in block-
ing buffer for 48 h at 4 °C. After 48 h, sections were 
washed 3 times in TBS-T and incubated with fluorescent 
secondary antibodies diluted 1:500 in blocking buffer for 
2 h at RT. After incubation in secondary antibodies, the 
sections were washed 2 times in TBS-T, followed by a 10 
min incubation in DAPI nuclear stain (1:5.000 in TBS-T), 
and 2 final washes in TBS. Sections were then mounted 
on microscope slides, Primary antibodies are described 
in Additional file  5: Table  S2 and secondary antibod-
ies were: Alexa Fluor 546 donkey anti-mouse and Alexa 
Fluor 488 donkey anti-rabbit (1:500, Life technologies). 
Confocal microscope Espectral Leica TCS SP5 was used 
to take the images. To quantify the percent of  CB2-TAU 
+ neurons, neuron counts were performed using Fiji 
Software (http:// fiji. sc/ Fiji) in aprox. 30 neurons/animal 
(n = 4 animals) of the hippocampus sections. To deter-
mine the area of the dendate gyrus, a total of 3 images 
per condition was analysed as follows. The images are 
transformed into 16 bits with the Image J program. Then, 
with the "Free Hand Selection" tool of the Imagen J pro-
gram, we manually selected only the dentate gyrus area 
of each image stained with DAPI. The dimension of the 
dentate gyrus inside the selected area was quantified 
using the "Measure" tool in Image J program and the raw 
results measured in inches were represented.
Sarkosyl‑soluble and ‑insoluble fractions of mouse 
hippocampi
Ipsilateral hippocampi were homogenized in Buffer A 
(0.1 M Buffer MES pH 7, 1 mM EDTA, 0.5 mM MgSO4, 
1 M sucrose, 1 mM NaF, 1 mM Na3VO4, 10 µg/ml leu-
peptin and phenylmethylsulfonyl fluoride (PMSF)). 
Homogenates were centrifuged at 20.000 rpm for 20 min 
at 4 °C. To obtain the sarkosyl-insoluble fraction (SI), the 
pellets were resuspended in RAB buffer described in [58], 
vortexed for 1 min at room temperature, incubated at 4 
°C overnight and then centrifuged at 69.000 rpm for 30 
min at 4 °C. The supernatants were collected as sarkosyl-
soluble fractions (SS) and the pellets, SI fractions, were 
resuspended in RAB buffer with 1 × SDS protein loading 
buffer and incubated at 95 °C for 5 min.
Protein extracts of mouse hippocampi
Protein lysates from ipsilateral and contralateral hip-
pocampi were homogenized in RIPA buffer (25 mM 
Tris–HCl pH 7.6, 150 mM NaCl, 1 mM EGTA, 1% NP-40, 
1% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 1 mM 
Na3VO4, 1 mM NaF, 1 μg/ml leupeptine). Homogenates 
were centrifuged at 13.000 rpm for 15 min at 4 °C.
Immunoblotting
25 μg of SS, SI, and protein extracts from mouse hip-
pocampi were resolved in SDS-PAGE and transferred to 
Immobilon-P membranes (Millipore). These membranes 
were analysed by using the following primary antibodies 
(Additional file 5: Table S2), and appropriate peroxidase-
conjugated secondary antibodies (Amersham). Proteins 
were detected by enhanced chemiluminescence (ECL). 
Images of the immunoblotting were analyzed using 
ImageJ, and the lane profiles were obtained in grayscale 
and uncalibrated optical density.
Human tissues
Samples and data from patients included in this study 
were provided by the Biobank Banco de Tejidos CIEN 
(PT17/0015/0014), integrated in the Spanish National 
Biobanks Network and they were processed follow-
ing standard operating procedures with the appropriate 
approval of the Ethics and Scientific Committees. Imme-
diately after brain extraction, midsagittal sectioning was 
performed to separate the right and left hemispheres of 
the brain. The left hemisphere was fixed in 10% buffered 
formalin for at least three weeks, and the hemisphere 
right were sliced and these slices were quick frozen fresh 
at − 50 °C (in NOVEC) and were immediately placed in 
at − 80 °C, where they were stored.
The frozen postmortem hippocampal tissues were 
obtained from four control (age 43, 58, 74 and 83 years) 
and four AD patients (age 80, 85, 86 and 88 years, Braak 
stages III-IV) within less than 6 h postmortem interval, 
according to the standardized procedures of Banco de 
Tejidos de la Fundación CIEN (Madrid, Spain). These 
frozen samples were used for RNA and qRT-PCR analy-
sis. The protocol used was similar to the one described 
in [39].
From the same patients, we obtained 5 μm paraffi-
nized sections from the hippocampus to perform immu-
nohistochemistry analysis. Briefly, human tissues were 
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deparaffinized before antigen retrieval (citric acid and 
sodium citrate 0.1 M). Tissues were left in a blocking 
solution for 1 h at room temperature and incubated with 
primary antibodies for 48 h. Primary antibodies were 
prepared in Dako REAL antibody diluent (Dako Diag-
nostics) and are described in Additional file 5: Table S2. 
Samples were incubated for 2 h at room temperature 
with the secondary antibodies Alexa Fluor 555 don-
key anti-rabbit and Alexa Fluor 488 donkey anti-mouse 
(1:500, Life technologies). Finally, tissues were incubated 
with Sudan Black (Sigma-Aldrich) to quench endogenous 
autofluorescence, rinsed 2 × in 70% ethanol and stained 
with DAPI for 15 min.
Statistical analysis
Data are presented as mean ± SEM (Standard Error of 
the Mean). To determine the statistical test to be used, we 
employed GraphPad Instat 3, which includes the analysis 
of the data to normal distribution via the Kolmogorov–
Smirnov test. Besides, statistical assessments of differ-
ences between groups were analysed (GraphPad Prism 
5, San Diego, CA) by unpaired Student’s t-tests when 
normal distribution and equal variances were fulfilled. 
Two-way or one-way ANOVA with posthoc Bonferroni 
or Tukey tests were also used, as appropriate.
Results
Overexpression of hTAU P301S induces specific changes 
in  CB2 expression in a mouse model of late stage 
tauopathy.
First, we determined if the neurodegeneration induced 
by TAU overexpression could produce alterations in 
the expression levels of the  CB2 receptor. To do this, 
we analysed  CB2 mRNA levels by qRT-PCR in the hip-
pocampus of transgenic mice that overexpressed the 
hTAU P301S protein at 12 months of age. At this age, 
mice present an exacerbated neurodegenerative picture 
with loss of neurons in the hippocampus and neuro-
inflammation [68], indicating that it is a late model of 
tauopathy. Our results indicated that hTAU P301S overex-
pression induced significantly Cnr2 mRNA expression 
in late stages of the pathology (9.44 ± 1.54) (Fig. 1a) and 
this change appears to be dependent on the presence of 
this mutant TAU form and its potential to aggregate. In 
support of this dependence, TAU-deficient mice, which 
are perfectly viable [27, 35], did not show any altera-
tions regarding  CB2 receptor. Moreover, this effect was 
specific towards the  CB2 receptor, as mRNA levels for 
Cnr1 did not change significantly among mice from 
the three different genotypes (Fig.  1b). Furthermore, 
previous evidence from our laboratory indicated that 
overexpression of hTAU P301L induced a neuroinflamma-
tory process [17, 21, 39], which is a key hallmark in the 
neuronal degeneration in tauopathies [41]. Analysis of 
mRNA expression levels of Iba1 and Gfap, microglial 
and astrocytic markers respectively, also confirmed 
that gliosis induced by hTAU P301S overexpression 
(4.85 ± 0.31 and 10.68 ± 1.12, respectively) was absent 
in TAU-knockout mice (Fig. 1c and d). In relation with 
neuroinflammation, we also detected that hTAU P301S 
overexpression significantly induced the mRNA levels 
of the transcription factor NF-κB (Rela) (1.98 ± 0.09), 
the master regulator of inflammation as well as the 
proinflammatory cytokines Il-1β (10.22 ± 0.64) and 
Tnf (12.98 ± 1.29) (Additional file  1: Figure S1). These 
results suggested that changes observed on  CB2 expres-
sion and inflammation were directly related to hTAU 
P301S overexpression.
Given that the elevation in the expression of the  CB2 
receptor in neurodegenerative disorders has been fre-
quently associated with its overexpression in glial ele-
ments (e.g. reactive microglia) elicited by the local 
inflammatory effects [7, 14, 15], we next investigated 
whether the increase found in hTAU P301S transgenic 
mice is a general effect or whether it is specific of any 
cell type. Therefore, we analysed specifically in which cell 
type  CB2 was overexpressed using co-immunofluores-
cence procedures. Our data indicated that around 50% 
of the neurons that overexpressed hTAU P301S are those 
that expressed the  CB2 receptor (Fig.  1e–f).  CB2 recep-
tor was preferentially expressed in neurons in which the 
formation of aggregates of TAU protein is observed (as 
detected with an antibody that identifies paired helical 
filaments (PHF) of TAU (Thr212/Ser214) (Fig. 1g). As a 
(See figure on next page.)
Fig. 1 Enhanced neuronal  CB2 expression due to hTAU 
P301S overexpression in a late stage tauopathy transgenic mouse model. Quantitative 
real‑time PCR determination of mRNA levels of a Cnr2, b Cnr1, c Iba1, d Gfap. All genes were normalized by Tbp (TATA‑box binding protein) mRNA 
levels, n = 4–5 samples ± SEM. Asterisks denote significant differences ****p < 0.0001, comparing the indicated groups with the wild type mice 
according to one‑way ANOVA followed by Tukey post‑test. e Neuronal localization of the  CB2 receptor in the hippocampus (CA2) of 12 months 
old hTAU P301S transgenic mice. Immunofluorescence with anti‑MAP2 (wild mice) or anti‑TAU (transgenic mice) (red), anti‑CB2 (green), and nuclear 
staining with DAPI (blue). Arrows point to hTAU P301S protein aggregates. f Quantification of  CB2‑TAU positive neurons in the CA2 hippocampal area. 
Number of TAU + or CB2‑TAU + neurons (n = 4 animals/experimental group) g Co‑localization of neuronal  CB2 receptor with aggregated TAU in the 
hippocampus (CA2). Immunofluorescence with anti‑PHF‑TAU (red), anti‑CB2 (green), and nuclear staining with DAPI (blue) in the transgenic mice. h 
Immunofluorescence with anti‑IBA1 (red), anti‑CB2 (green), and nuclear staining with DAPI (blue)
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control, MAP2 protein was used as a neuronal marker in 
the wild type mice. The finding of overexpression of the 
 CB2 receptor in neurons in a neurodegenerative pathol-
ogy is not frequent [59], but it is not unexpected, given 
the incipient evidence supporting that  CB2 receptors may 
be also present in neurons in the healthy brain [44, 65]. 
To confirm whether this overexpression was specific or 
whether it also occurred in glial elements, we conducted 
a similar double-staining analysis, using IBA1, a marker 
of microglial cells. In this case, it was again observed that 
 CB2 was expressed only at the neuronal level (CA2, CA3, 
and dentate gyrus), with no co-localization in the micro-
glia (Fig.  1h). In turn, the difference in microglial mor-
phology between wild-type mice (quiescent-non-reactive 
form) and transgenic mice (ameboid-reactive form) was 
strongly evident, confirming the presence of a reactive 
microgliosis. These data clearly indicated that hTAU P301S 
induced selective neuronal  CB2 expression in a late-stage 
tauopathy mouse model.
Increased neuronal  CB2 receptor expression is an early 
event in tauopathies.
Our next objective was to determine if the increase in 
the expression of  CB2 receptors was also seen at earlier 
stages in the pathology, so that it may be considered as 
an early event possibly contributing to the pathogenesis. 
In 7 months old hTAU P301S transgenic mice, we detected 
a significant slight increased expression of  CB2 recep-
tors, at mRNA (1.24 ± 0.06) and protein level (Fig. 2a and 
b), without alterations in the mRNA expression of Cnr1, 
Fig. 2 Increased  CB2 expression is an early event in tauopathies. Analysis of 7 months old hTAU 
P301S transgenic mice. a Neuronal location of the  CB2 
receptor in the hippocampus (CA2) of 7 months old hTAU P301S transgenic mice. Immunofluorescence with anti‑mTAU (wild type mice) or anti‑hTAU 
(transgenic mice) (red), anti‑CB2 (green), and nuclear staining with DAPI (blue). b Quantification of Cnr2 and Cnr1 mRNA levels, n = 4 samples ± SEM. 
The data has been processed with Student’s t‑test analysis to determine the significance of the changes. The asterisks represent the difference in 
significance * p < 0.05. c Neuronal location of the  CB2 receptor in the hippocampus (CA2) in the AAV‑hTAU 
P301L mouse model. Immunofluorescence 
with anti‑hTAU (red), anti‑CB2 (green), and nuclear staining with DAPI (blue). d Analysis of wild type mice injected into the ipsilateral hippocampus 
with the AAV‑hTAU P301L vector for 3 weeks. Quantification of Cnr2 and Cnr1 mRNA levels, n = 4–6 samples ± SEM. The data has been processed with 
Student’s t‑test analysis to determine the significance of the changes. The asterisks represent the difference in significance **** p < 0.0001
Page 8 of 18Galán‑Ganga et al. acta neuropathol commun            (2021) 9:90 
RelA, Il-1β and Tnf (Additional file 1: Figure S1). To elim-
inate the possibility that these changes are due to adap-
tations during development, we confirmed these results 
in another early model of tauopathy consisting of mice 
stereotaxically injected into the right hippocampus with 
an AAV-hTAU P301L vector for 21 days [17, 21, 39] (Fig. 2c 
and d). Analysis of the samples by qRT-PCR showed that 
overexpression of hTAU P301L induced a very significant 
increase in Cnr2 mRNA levels (5.88 ± 0.67) (Fig. 2d). As 
in the transgenic mouse model, this effect was specific for 
 CB2, since the expression of Cnr1 did not show significant 
changes. These results reproduced what was observed in 
the hippocampus of the 12-month-old transgenic mice 
that overexpressed the hTAU P301S protein (Figs. 1 and 2a 
and b), confirming that these are events that occur at an 
early stage of the pathology, possibly contributing to the 
Fig. 3 hTAU P301L overexpression increased AEA levels in the hippocampus. a Scheme of the ECS: main receptors, ligands, and enzymes involved 
in the endocannabinoid signalling pathway. b Analysis of AEA and 2‑AG levels (pmol/g) measured by LC–MS on the ipsilateral and contralateral 
hippocampi from wild type mice injected with the AAV‑hTAU P301L, n = 8 samples ± SEM. c qRT‑PCR determination of mRNA levels of Napepld, Dagla, 
and Dglb, involved in the synthesis of AEA and 2‑AG, and d Faah and Mgll, involved in the degradation of AEA and 2‑AG. Cox2 and Alox15, involved 
in other pathways. All measures were normalized by Tbp mRNA levels. n = 5 samples ± SEM. Asterisks denote significant differences *p < 0.05, 
according to Student’s t‑test
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pathogenesis. Finally, we confirmed that  CB2 expression 
also takes place at the neuronal level in this additional 
tauopathy mouse model, using immunofluorescence for 
 CB2 and TAU in hippocampus sections (Fig. 2c). As seen 
in Fig.  1e, there was co-localization between the  CB2 
receptor and neurons that overexpress the hTAU P301S or 
hTAU P301L protein, confirming again its expression at the 
neuronal level.
AEA levels are induced by overexpression of hTAU P301L 
in the hippocampus.
Besides cannabinoid receptors, we must take into con-
sideration that TAU overexpression may also induce 
changes in other elements of the endocannabinoid sys-
tem. Therefore, we analysed the levels of ECs and the 
enzymes involved in their synthesis/inactivation in hip-
pocampal samples of mice injected stereotaxically into 
the right hippocampus with an AAV-hTAU P301L vec-
tor (ipsilateral). As we have previously mentioned, AEA 
and 2-AG are the two main ECs, with different affinities 
for  CB1 and  CB2 receptors [51] (Fig. 3a). LC–MS analy-
ses showed that hTAU P301L overexpression increased 
significantly the levels of AEA (Control: 19.64 ± 2.60; 
hTAU P301L: 27.13 ± 2.18) and to a lesser extent (only 
as a trend), those of 2-AG (Control: 175,773 ± 26,855; 
hTAU P301L: 248,234 ± 38,184) (Fig. 3b). In order to check 
whether these results could be due to alterations in the 
expression of the enzymes involved in their synthesis, we 
measured mRNA levels of Napepld, Dagla, and Daglb, 
but we did not observe any changes (Fig.  3c). Then, we 
analysed mRNA levels of Faah, Mgll, Cox2, and Alox15 
(Fig. 3d), enzymes involved in the degradation of ECs and 
other associated pathways. In this case, we found a sta-
tistically significant decrease in the expression of Faah 
(0.854 ± 0.070) that could be responsible for the increase 
in AEA levels, whereas a numerical trend towards a 
decrease could be appreciated for Mgll that could be 
related to the trend found for 2-AG levels.
CB2 receptor deficiency ameliorated cognitive impairment 
and reduced degeneration of the granular cell layer 
of the dentate gyrus induced by hTAU P301L overexpression.
All our results indicated that the overexpression of TAU 
increases the neuronal levels of  CB2 in different tauopa-
thy models. To determine if this increase of  CB2 is a 
mechanism of the brain to fight against neurodegenera-
tion or, on the contrary, is contributing to the patho-
genesis, we overexpressed hTAU P301L in  CB2-deficient 
mice (AAV-hTAU P301L model) and wild type animals. 
Then, to assess whether the  CB2 expression affects the 
recognition memory alterations induced by TAU over-
expression in the hippocampus, we performed the NOR 
test [43] two days before sacrifice. As specific controls 
for both genotypes, we used wild type or  CB2-deficient 
mice from the same age, without hTAU P301L overexpres-
sion (Sham). Cnr2+/+ mice injected with the AAV-hTAU 
P301L in the hippocampus showed the expected significant 
decrease in the discrimination index compared to sham 
animals (Cnr2+/+ Sham: 0.329 ± 0.042; Cnr2+/+ -AAV-
hTAU P301L: 0.118 ± 0.051; Cnr2−/− Sham: 0.311 ± 0.022; 
Cnr2−/− -AAV-hTAU P301L: 0.312 ± 0.029). However, the 
lack of  CB2 receptors in Cnr2−/− mice avoided this cog-
nitive impairment caused by hTAU P301L overexpression 
(Fig.  4a). On the other hand, the recognition memory 
was similar in Cnr2−/−-sham mice compared to Cnr2+/+-
sham animals. These results suggested that the expres-
sion of  CB2 could be involved in mechanisms of neuronal 
plasticity associated with recognition memory. We 
already have described that this tauopathy mouse model 
has alterations in synaptic plasticity [17, 21]. To assess 
the implication of  CB2 in this mechanism, we determined 
the expression levels of Brain-Derived Neurotrophic Fac-
tor (BDNF), involved in the acquisition and consolidation 
of overlapping spatial memories in the dentate gyrus [49]. 
In Cnr2+/+ mice, hTAU P301L overexpression significantly 
decreased Bdnf mRNA levels (0.784 ± 0.073) on the ipsi-
lateral hippocampus (Fig. 4b). However, Bdnf expression 
levels did not change due to hTAU P301L overexpression 
in Cnr2−/− mice and remained the same as in Cnr2+/+-
contralateral samples (Fig.  4b). These results inversely 
correlated with  CB2 receptor expression levels, measured 
by qRT-PCR and immunofluorescence (Additional file 2: 
Figures  S2), where higher levels of Cnr2 (1.714 ± 0.104) 
correlated with lower Bdnf expression. In the Additional 
file 2: Figures S2 it can be observed that the overexpres-
sion of hTAU P301L induced  CB2 at the neuronal level, 
corroborating previous data (Figs.  1e and 2c), and this 
increase is specific since it did not occur in  CB2-deficient 
mice. Thus, it seems that the increase in  CB2 expression 
induced by hTAU P301L overexpression in neurons is detri-
mental for the cognitive status.
Within the hippocampus, the area of the dentate gyrus 
is thought to contribute to the formation of new epi-
sodic memories [26] and the spontaneous exploration 
of novel environments, among other functions. There-
fore, we determined if there was a correlation between 
the data we obtained in the NOR (Fig.  4a) and altera-
tions in the structure of the dentate gyrus. Staining of 
the dentate gyrus area with DAPI, a fluorescent staining 
that binds strongly to adenine–thymine rich regions in 
DNA, indicated that hTAU P301L overexpression induced 
the loss of part of the granular cell layer in Cnr2+/+ mice 
(Fig. 4d). Nevertheless, this loss was partially attenuated 
in Cnr2−/− mice injected with AAV-hTAU P301L, as can 
be observed in the quantification of the area (Cnr2+/+-
contra: 29,108 ± 3266; Cnr2+/+-ipsi: 13,876 ± 1670; 
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Fig. 4 Cognitive impairment induced by hTAU P301L overexpression is prevented in Cnr2−/− mice. a Recognition memory was tested by NOR test 
in control mice (Sham), and Cnr2+/+ and Cnr2−/− mice overexpressing hTAU P301L (n = 8–15 per experimental group). b qRT‑PCR determination of 
mRNA levels of Bdnf, normalized by Tbp mRNA levels, n = 5–7 samples ± SEM. Asterisks denote significant differences with *p < 0.05, comparing 
each group with the contralateral hippocampi from Cnr2+/+ mice or the indicated groups, according to two‑way ANOVA followed by Bonferroni 
post‑test. Reduction in the granular cell layer from the dentate gyrus due to hTAU P301L overexpression is attenuated in Cnr2−/− mice. c Quantification 
of the area stained with DAPI (arbitrary units) in the dentate gyrus from Cnr2+/+ and Cnr2−/− mice injected with AAV‑hTAU P301L. n = 3–4 
samples ± SEM. Asterisks denote significant differences with *p < 0.05 comparing the ipsilateral side with the contralateral side of the indicated 
groups, according to two‑way ANOVA followed by Bonferroni post‑test. d Immunofluorescence staining in hippocampal sections from Cnr2+/+ and 
Cnr2−/− mice injected with AAV‑hTAU P301L (n = 3–4 per experimental group). Blue, DAPI. Green, anti‑CALBINDIN‑D28K
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Cnr2−/−-contra: 33,628 ± 3246; Cnr2−/−-ipsi: 
20,565 ± 2222 (Fig.  4c). Concerning synaptic plasticity, 
we analysed the expression levels of CALBINDIN-D28K, 
a member of the calcium-binding protein superfam-
ily whose expression strongly correlates with protection 
against TAU neurodegeneration [21]. Immunofluores-
cence analysis of the dentate gyrus showed that hTAU 
P301L overexpression reduced CALBINDIN-D28K expres-
sion levels in the granular layer in Cnr2+/+ mice (Fig. 4d) 
and to a lesser extent in Cnr2−/− mice (Cnr2+/+-contra: 
186,160 ± 29,602; Cnr2+/+-ipsi: 47,521 ± 5462; Cnr2−/−-
contra: 159,640 ± 12,124; Cnr2−/−-ipsi: 91,311 ± 22,406). 
Taken together, these results suggest that the lack 
of  CB2 receptor protects against TAU induced 
neurodegeneration.
p‑TAU insolubility is reduced in  CB2‑deficient mice
In tauopathies, abnormal metabolism of TAU protein 
leads to its intracellular accumulation, hyper- or aber-
rant phosphorylation and formation of neurofibrillary 
tangles, which can lead to protein toxicity, cell death and 
neurodegeneration [33]. We analysed if the levels of solu-
ble (SS) and insoluble (SI) TAU fractions depend on  CB2 
expression, using sarkosyl extraction as a standard pro-
tocol for investigating insoluble TAU aggregates in the 
brain [58].
First, we determined that both genotypes expressed 
similar levels of MAPT mRNA in the injected side 
(Fig.  5a). It has been described that sarkosyl-insoluble 
(SI) TAU correlates with the pathological features of 
tauopathy. In the ipsilateral hippocampi, the Cnr2−/− 
mice showed decreased hyperphosphorylated TAU at 
Ser202/Thr205 in the sarkosyl-insoluble fraction (SI) 
in comparison to Cnr2+/+ mice (Fig. 5b). Regarding the 
soluble fraction SS, we observed the opposite effect. Our 
data suggest that the absence of  CB2 receptor modulates 
TAU levels by increasing the soluble fraction (SS), indi-
cating a reduction of p-TAU aggregates.
The absence of  CB2 receptor does not change 
the inflammation status when overexpressing hTAU P301L
As we mentioned before, along with alterations in neu-
ronal plasticity and proteostasis, neuroinflammation is a 
key element in neurodegenerative processes [41]. Con-
cerning  CB2, previous evidence from other laboratories 
pointed out at the possible role of  CB2 in modulating 
microglial activation in different neurodegenerative dis-
orders such as AD [12, 16], so we explored whether the 
up-regulatory response experienced by  CB2 receptors in 
our tauopathy model could have any relation with the 
inflammatory response. Our results indicated that over-
expression of hTAU P301L was followed by the expected 
proinflammatory scenario reflected by increased expres-
sion of markers of astrogliosis (Gfap), microgliosis (Iba1) 
and proinflammatory cytokines (Il-1β and Tnf), but this 
was seen at the same extent in both genotypes (Addi-
tional file 3: Figures S3). Therefore, our data support that 
the  CB2 receptor does not appear to play a relevant role 
Fig. 5 TAU‑SI levels are reduced in Cnr2−/− mice. a qRT‑PCR determination of mRNA levels of MAPT. b Ipsilateral hippocampal tissue obtained from 
Cnr2+/+ and Cnr2−/− AAV‑hTAU P301L injected mice were separated into SS and SI fractions. Levels of p‑TAU‑AT8 were analysed in by immunoblotting 
and their respective protein quantifications. n = 3 samples per experimental group ± SEM. Asterisks show significant differences with **p < 0.01 
comparing each group according to a Student’s t‑test
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at the level of neuroinflammation induced by hTAU P301L 
overexpression.
Increased expression of neuronal  CB2 in post‑mortem 
tissues from AD patients
Our preclinical data indicated that overexpression of 
TAU P301L induces an increase in the expression of neu-
ronal  CB2 and that this induction was toxic to the neu-
ron in animal models. To determine that aberrant TAU 
aggregation (formation of neurofibrillary tangles (NFT)) 
in patients lead to similar results, in our last objective, we 
wanted to work with tissues from patients with tauopa-
thies. We assume that tauopathies are an heterogenous 
group of pathologies and that including TAU-dependent 
cases of the other pathologies (e.g. TAU-dependent fron-
totemporal dementia) would have been desirable, but, 
due to its low incidence, it is difficult to collect a suffi-
cient number of cases of this tauopathy, so we finally 
worked with AD, the more frequent tauopathy. We used 
samples from AD patients with Braak stages III-IV, when 
they present symptoms of incipient AD and the entorhi-
nal and transentorhinal layers are affected (Fig.  6a) to 
determine  CB2 status. Analysis of mRNA levels from 
both cannabinoid receptors by qRT-PCR showed that 
CNR2 expression was significantly increased in AD 
patients (5.567 ± 1.422) compared to controls whereas 
CNR1 levels were 50% decreased (0.525 ± 0.155) (Fig. 6b), 
indicating that the ECS is deregulated in AD, as described 
before [20].
Next, we explored the cell substrates in which the up-
regulatory response of  CB2 receptors takes place, so 
we analysed the location of  CB2 receptors in AD, using 
immunofluorescence assays. Interestingly, we observed 
overexpression of  CB2 receptors in those neurons that 
presented TAU neurofibrillary tangles (Fig. 6c), corrobo-
rating the results obtained in the murine models. These 
data confirmed that aberrant TAU accumulation induces 
 CB2 receptor expression in human patients as in tauopa-
thy mouse models.
Discussion
Aberrant TAU plays a role in the pathogenesis of a vari-
ety of neurodegenerative diseases, and the study of the 
implication of TAU in those pathologies suggested the 
involvement of different molecular mechanisms. Among 
them, our results demonstrate for the first time that TAU 
overexpression increased levels of  CB2 receptors at neu-
ronal level and that  CB2-deficiency protects against TAU 
harmful mechanism.
Although there is no specific study regarding the 
interaction between  CB2 and TAU, several studies in 
AD models indicate a controversial role of  CB2 in the 
progression of the disease. In a triple transgenic mouse 
model (mutations in the APP, presenilin 1 (PSEN1) 
and TAU genes), the deletion of  CB2 induces AD-like 
TAU pathology and memory impairment [67]. Similar 
results were observed in another transgenic AD APP-
based mouse model, in which  CB2 receptor deficiency 
increased amyloid pathology and altered TAU pro-
cessing [36]. Other studies indicate that in the APP/
PSEN1 AD mouse model, the lack of  CB2 receptor 
intensifies cortical Aβ deposition and rises the levels 
of soluble Aβ40 [5]. However,  CB2 receptor ablation 
does not affect the survival of APP/PSEN1 mice and 
has no impact on memory impairment or TAU hyper-
phosphorylation. In this AD mouse model, it has been 
shown that the treatment with JWH-133, a specific 
 CB2 cannabinoid receptor agonist, induced cognitive 
improvement due to decreased microglial reactivity 
and reduced expression of pro-inflammatory cytokines 
IL-1β, IL-6, TNFα, and IFNγ [7]. However, it has been 
also demonstrated that  CB2 deletion also improves 
cognitive and learning deficits in another transgenic 
APP/PSEN1/CB2−/− mice [62], in which reduced neu-
ronal loss and decreased plaque levels were observed. 
Interestingly, in this study, authors demonstrated that 
the microglia surrounding plaques showed a less acti-
vated morphology in the absence of  CB2 receptor, being 
the plaques smaller and more condensed than in APP/
PSEN1 mice. Altogether, these data indicate divergent 
effects of  CB2 related to APP or TAU. To date, about 
AD, in studies relating to the  CB2 receptor with pathol-
ogy, only models based exclusively on overexpression of 
the APP protein have been used, and no studies have 
been carried out on models based on the TAU pro-
tein, so our results are extremely novel and innovative. 
In this context, our results regarding the involvement 
of  CB2 receptor in neurodegenerative processes that 
only implicate TAU protein shed light on the molecu-
lar mechanisms involved. Besides, it must be taken into 
Fig. 6 CB2 is increased in neurofibrillary tangle TAU positive neurons from AD patients. a Scheme of the different Braak stages of AD progression 
in the human brain: Stages I‑II (transenthorinal), stages III‑IV (limbic), and stages V‑VI (neocortical) (Modified from http:// www. thehu manbr ain. info/ 
at the hippocampus level). b qRT‑PCR determination of mRNA levels of CNR1 and CNR2. Both measures were normalized by TBP mRNA levels. 
n = 3–4 ± SEM. Asterisks denote significant differences *p < 0.05, comparing the AD patients with the control condition according to Student’s t‑test. 
c Double immunofluorescence staining of 15 μm‑thick sections of hippocampal tissue from control (n = 4) and AD (n = 4) patients. Green, anti‑CB2. 
Red, anti‑TAU‑HT7. Blue, DAPI
(See figure on next page.)
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account that the possible beneficial effects that have 
been seen with the activation of the  CB2 receptor in 
these AD models are mainly based on its anti-inflam-
matory effects related to its expression in the microglia 
[4, 66], which may indicate that the direction in which 
the  CB2 receptor should be modulated may depend on 
the type of neurotoxic event to be controlled: activa-
tion against inflammatory events in APP-based models 
and inhibition against neuronal deterioration in TAU-
dependent models. If this is so, this should be neces-
sarily taken into consideration when these treatments 
progress towards the clinical scenario given the com-
plexity of neurodegenerative events in AD. In relation 
to this personalized medicine, it is also interesting to 
highlight the implication that modulation of the  CB2 
receptor would have in the development of disease-
modifying drugs for frontotemporal dementia (FTD) 
spectrum disorders, although to date no change in  CB2 
levels (neither in microglia nor in neurons) has been 
described in this pathology, so it would be interesting 
to determine the status of  CB2 and its cellular location. 
FTLD are classified according to the predominant pro-
tein that accumulates abnormally in cells and 40% of all 
FTLD are associated with aberrant TAU accumulation 
[52]. Therefore, the pharmacological modulation of  CB2 
as a therapeutic strategy for FTLD should be person-
alized, based on the molecular alterations displayed by 
the different type of patients.
In our study, we have shown that the neuronal induc-
tion of  CB2 levels by overexpression of TAU is an event 
that is maintained throughout the neurodegenerative 
process until late stages of the disease and that it is 
dependent on TAU aggregation, since it is not altered 
in TAU-knockout mice. P301L or P301S mutations in 
the TAU protein prevent the anchoring of TAU to the 
microtubules and favor the aggregation of the protein, 
which happens, although by other mechanisms, in AD 
[19]. Thus, in both scenarios we have a neurotoxic form 
of the TAU protein, and in both cases the expression of 
 CB2 was induced at the neuronal level.
Our results indicated that overexpression of hTAU 
P301L increases AEA levels possibly by decreasing the 
expression of FAAH, an enzyme involved in its degrada-
tion. It has been reported that pharmacological eleva-
tion of anandamide impairs short-term memory in the 
hippocampus [31], indicating that in our AAV-hTAU 
P301L mouse model the increase in AEA is implicated 
in cognitive impairment. These results are the first evi-
dence of alterations in the ECS in a tauopathy mouse 
model. Nevertheless, it remains to be determined if 
variations in the levels of ECs would also be related to 
changes in the protein levels of these enzymes and their 
enzymatic activity, something already described for 
other neurodegenerative disorders [24].
To determine whether the increase in  CB2 levels is 
beneficial or toxic to the neuron, we analysed the effect 
of hTAU P301L overexpression in  CB2-deficient mice. The 
results clearly indicate that the absence of  CB2 improves 
the cognitive impairment and the synaptic plasticity 
(Fig.  4) induced by hTAU P301L overexpression. Similar 
observations were found in a study of  CB2 receptors in 
cerebral malaria, where the benefits were reached by 
blocking the receptor or ablating its gene expression [2]. 
However, this contrasts with most of the literature on 
 CB2 receptor in other neurodegenerative/neuroinflam-
matory disorders, in which the benefits were reached 
after the activation of this receptor [6, 14, 25, 28, 32, 50]. 
The difference compared with our current study may be 
in the cell type where the  CB2 receptor is located: glial 
versus neuronal location. Although classical expression 
of  CB2 has always been related to microglia and neuro-
inflammatory processes [16], our results suggest that 
in relation to TAU,  CB2 does not play an essential role 
in inflammation. Moreover, we observed that in all the 
tauopathy mouse models used and in AD postmortem 
brain samples increased  CB2 expression occurs at neu-
ronal levels. This agrees with recent evidence that indi-
cates that the  CB2 receptor can also be expressed at the 
neuronal level [44, 65], being involved in neuroplasticity 
processes like learning and memory [34], by being able to 
induce hyperpolarization in hippocampal neurons [55]. 
In line with our results, it has been demonstrated that 
 CB2 disruption enhanced spatial working memory, while 
their overexpression reduced anxiety levels [44]. Related 
to the participation of the  CB2 receptor in regulating 
memory, one of the main characteristics presented by 
patients with Alzheimer’s disease (AD) is memory loss. 
In this work, we have confirmed an increase in CNR2 
expression in samples from AD patients. Increased  CB2 
protein expression is present in the TAU damaged neu-
ron, with total co-localization. These results indicate that 
 CB2 overexpression could be detrimental for neuroplasti-
city and neuronal survival and be associated with disease 
progression. All these pieces of evidence indicate that 
 CB2 expression has different roles depending on the cell-
type where it is expressed in the mature hippocampus 
and is important in regulating memory. Taken together, 
it could be speculated that when the  CB2 receptor is 
expressed in the microglia, its activation has anti-inflam-
matory and beneficial effects against neurodegeneration, 
but when  CB2 receptor is overexpressed at the neuronal 
level, its functionality changes radically, having a detri-
mental effect against neurodegeneration.
Regarding the mechanism by which the absence of  CB2 
prevents TAU toxicity, our data suggest that it could be 
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due to an improvement in the solubility of TAU  (CB2 
deficiency led to impairment of TAU aggregate forma-
tion). It is commonly accepted that pathological features 
of tauopathy correlate with the levels of insoluble TAU 
aggregates (SI) in the brain. We found that Cnr2−/− mice 
had less hyperphosphorylated TAU aggregates than 
Cnr2+/+ mice in the ipsilateral side of hTAU P301L over-
expression in the hippocampus, although they had simi-
lar MAPT expression levels. It has been described that 
 CB2 receptors have been shown to regulate a plethora 
of kinases, including PI3K/AKT/GSK-3, JNK and p38 
[22], which are linked to TAU phosphorylation [47, 54, 
70]. These results suggested that the lack of  CB2 could 
be implicated in reducing TAU phosphorylation. Further 
experiments will be needed to determine the involvement 
of these kinases in the removal of TAU aggregates and 
the involvement of the CB2 receptor in these processes.
Conclusions
This study describes for the first time how TAU overex-
pression increases  CB2 receptor expression at the neu-
ronal level in the hippocampus, being an early event in 
tauopathies. Unlike  CB2 induction in microglia, this neu-
ronal  CB2 overexpression enhances the neurodegenera-
tive process associated with the TAU protein. This study 
paves the way to propose  CB2 antagonists (or negative 
allosteric modulators) as an entirely novel therapeutic 
approach in tauopathies.
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Analysis of mRNA levels of inflammatory genes RelA, Tnf and Il‑1β in 12 
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to determine the significance of the changes. The asterisks represent the 
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Cnr2. Measures were normalized by Tbp mRNA levels. n=5‑7 samples ± 
SEM. Asterisks denote significant differences with ***p<0.001, comparing 
each group with the contralateral hippocampi from  Cnr2+/+ mice or the 
indicated groups, according to two‑way ANOVA followed by Bonfer‑
roni post‑test. (B) Double immunofluorescence staining of 30 μm‑thick 
sections of contralateral and ipsilateral hippocampus from  Cnr2+/+ mice 
injected with AAV‑hTAUP301L (n=3). The ipsilateral side from  Cnr2‑/‑ was 
used as a control (n=1). Green, anti‑CB2. Red, anti‑TAU‑HT7. Blue, DAPI.
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genes were normalized by Tbp mRNA levels. n=5‑7 samples ± SEM. Aster‑
isks denote significant differences with *p<0.05, **p<0.01, and ***p<0.001, 
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